Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion.
Read the full article: Sanofi to Acquire Blueprint Medicines, Expanding Portfolio in Rare Immunological Disease and Adding Early-Stage Pipeline in Immunology //
Source: https://www.prnewswire.com/news-releases/sanofi-to-acquire-blueprint-medicines-expanding-portfolio-in-rare-immunological-disease-and-adding-early-stage-pipeline-in-immunology-302470376.html